Abstract CA 19.9 antigen is mainly secreted by biliary and pancreatic duct celis.
transaminases, fibrosis, and biliary iron deposits. Hepatic CA 19.9 was located within the cytoplasm of bile duct and cholangiolar cells. In conclusion, this study shows that a mild, reversible, and non-specific increase in serum CA 19.9 is common in genetic haemochromatosis patients and shows that this increase is related to iron excess, directly or through associated liver damage. The unexplained finding of a mild increase in serum CA 19.9 should lead, in a patient with no diagnosis, to the search for liver iron overload, and, in a patient with untreated genetic haemochromatosis, not to further diagnostic procedures unless this finding persists after completion of the venesection treatment.
(Gut 1994; 35: 1107-1111) CA 19.9 antigen, a mucinel 2 containing sialylated lacto-N-fucopentaoseII,3-7 is widely used as a marker for pancreas cancer. [8] [9] [10] [11] [12] [13] [14] A large number of reports, however, have focused on the increase of serum CA 19.9 in other malignancies as well as in non-malignant conditions,15-19 especially chronic and acute liver diseases.4 17 20-24 The liver is the main site for CA 19.9 metabolism. Indeed, biliary cells are responsible for CA 19 (Fig 2) , and total bilirubin was seen when comparing before and after treatment data (Table) . 1 > 23 9 (20) All genetic haemochromatosis liver biopsy specimens studied (n=24) were positive for CA 19.9. In all cases, positivity was located within the cytoplasm of bile duct cells: iron overloaded ducts presented with an intense black positivity that differed from the faint staining of unloaded ducts. In addition, in fibrotic haemochromatotic livers, a noticeable positivity was seen in periportal cholangiolar cells (Fig 3) . A correlation (p=0 02) was found between the presence of iron deposits within biliary cells and the increase of serum CA 19.9 (Fig 4) Discussion This study shows that serum CA 19.9 is increased in patients with genetic haemochromatosis, is correlated not only with the amount of liver and biliary iron but also with liver function tests abnormalities and the presence of fibrosis, and also decreases after completion of the venesection programme. It was also shown that hepatic CA 19.9 is overexpressed within iron overloaded bile duct cells in genetic haemochromatosis. The decrease in serum CA 19.9 after de-ironation implies that iron overload is responsible for changes in CA 19.9 metabolism. No definite conclusion can be drawn, however, about the mechanism of these disturbances, which may be either directly related to iron or secondary to iron induced liver damage. A role of pancreas iron overload seems unlikely. Indeed, no difference was found in serum CA 19.9 according to the presence or absence of diabetes. The role of liver is more probable. Indeed, biliary cells participate in CA 19.9 metabolism. CA 19.9 synthesis is located in these cells22 25 and entails a sialyl transferase activity,5 35 which is increased in inflammatory liver process.35 36 Mild lymphocytic and histiocytic liver inflammation and sideronecrosis have been described in genetic haemochromatosis.28 Therefore, an increase in sialyl transferase activity may be suggested as a factor of increase in CA 19.9 biliary synthesis. This study shows that a mild -that is, up to four times the upper limit of normalreversible, and non-specific increase in serum CA 19.9 is common in patients with genetic haemochromatosis. It also shows that this increase is related to iron excess, directly or through associated liver damage, especially cytolysis but not overt cholestasis or fibrosis as commonly reported in other chronic liver diseases. From a practical point of view, the unexplained finding of a mild increase in serum GA 19.9 should lead, in a patient with no diagnosis, to the search for liver iron overload and, in a patient with untreated genetic haemochromatosis, not to further diagnostic procedures unless this finding persists after completion of the venesection treatment.
